A pilot study of weekly brentuximab vedotin in patients with CD30+malignancies resistant to brentuximab vedotin every 3 weeks

被引：4
作者：
Poston, Jacqueline N. [1 ,2 ,3 ,4 ]
Fromm, Jonathan R. [4 ,5 ]
Rasmussen, Heather A. [1 ]
Shustov, Andrei R. [2 ,3 ,4 ]
Libby, Edward N., III [1 ,2 ,4 ]
Smith, Stephen D. [1 ,2 ,4 ]
Gooley, Ted [2 ]
Gopal, Ajay K. [1 ,2 ,4 ]
机构：
[1] Univ Washington, Dept Med, Div Med Oncol, Seattle, WA 98195 USA
[2] Fred Hutchinson Canc Res Ctr, Clin Res Div, 1124 Columbia St, Seattle, WA 98104 USA
[3] Univ Washington, Dept Med, Div Hematol, Seattle, WA USA
[4] Seattle Canc Care Alliance, Seattle, WA 98109 USA
[5] Univ Washington, Dept Lab Med, Div Hematopathol, Seattle, WA 98195 USA
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2019年 / 186卷 / 01期
关键词：
Hodgkin lymphoma; anaplastic large cell lymphoma; brentuximab vedotin; CD30; HODGKIN LYMPHOMA;
D O I：
10.1111/bjh.15742
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：159 / 162
页数：4
相关论文
共 9 条
  • [1] Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies
    Bartlett, Nancy L.
    Chen, Robert
    Fanale, Michelle A.
    Brice, Pauline
    Gopal, Ajay
    Smith, Scott E.
    Advani, Ranjana
    Matous, Jeffrey V.
    Ramchandren, Radhakrishnan
    Rosenblatt, Joseph D.
    Huebner, Dirk
    Levine, Pamela
    Grove, Laurie
    Forero-Torres, Andres
    [J]. JOURNAL OF HEMATOLOGY & ONCOLOGY, 2014, 7
  • [2] Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma
    Chen, Robert
    Gopal, Ajay K.
    Smith, Scott E.
    Ansell, Stephen M.
    Rosenblatt, Joseph D.
    Savage, Kerry J.
    Connors, Joseph M.
    Engert, Andreas
    Larsen, Emily K.
    Huebner, Dirk
    Fong, Abraham
    Younes, Anas
    [J]. BLOOD, 2016, 128 (12) : 1562 - 1566
  • [3] Revised response criteria for malignant lymphoma
    Cheson, Bruce D.
    Pfistner, Beate
    Juweid, Malik E.
    Gascoyne, Randy D.
    Specht, Lena
    Horning, Sandra J.
    Coiffier, Bertrand
    Fisher, Richard I.
    Hagenbeek, Anton
    Zucca, Emanuele
    Rosen, Steven T.
    Stroobants, Sigrid
    Lister, T. Andrew
    Hoppe, Richard T.
    Dreyling, Martin
    Tobinai, Kensei
    Vose, Julie M.
    Connors, Joseph M.
    Federico, Massimo
    Diehl, Volker
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (05) : 579 - 586
  • [4] Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma
    Connors, J. M.
    Jurczak, W.
    Straus, D. J.
    Ansell, S. M.
    Kim, W. S.
    Gallamini, A.
    Younes, A.
    Alekseev, S.
    Illes, A.
    Picardi, M.
    Lech-Maranda, E.
    Oki, Y.
    Feldman, T.
    Smolewski, P.
    Savage, K. J.
    Bartlett, N. L.
    Walewski, J.
    Chen, R.
    Ramchandren, R.
    Zinzani, P. L.
    Cunningham, D.
    Rosta, A.
    Josephson, N. C.
    Song, E.
    Sachs, J.
    Liu, R.
    Jolin, H. A.
    Huebner, D.
    Radford, J.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (04) : 331 - 344
  • [5] A Phase I Weekly Dosing Study of Brentuximab Vedotin in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies
    Fanale, Michelle A.
    Forero-Torres, Andres
    Rosenblatt, Joseph D.
    Advani, Ranjana H.
    Franklin, Anna R.
    Kennedy, Dana A.
    Han, Tae H.
    Sievers, Eric L.
    Bartlett, Nancy L.
    [J]. CLINICAL CANCER RESEARCH, 2012, 18 (01) : 248 - 255
  • [6] Characterization and Purification of Neoplastic Cells of Nodular Lymphocyte Predominant Hodgkin Lymphoma from Lymph Nodes by Flow Cytometry and Flow Cytometric Cell Sorting
    Fromm, Jonathan R.
    Thomas, Anju
    Wood, Brent L.
    [J]. AMERICAN JOURNAL OF PATHOLOGY, 2017, 187 (02) : 304 - 317
  • [7] Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma
    Herrera, Alex F.
    Moskowitz, Alison J.
    Bartlett, Nancy L.
    Vose, Julie M.
    Ramchandren, Radhakrishnan
    Feldman, Tatyana A.
    LaCasce, Ann S.
    Ansell, Stephen M.
    Moskowitz, Craig H.
    Fenton, Keenan
    Ogden, Carol Anne
    Taft, David
    Zhang, Qu
    Kato, Kazunobu
    Campbell, Mary
    Advani, Ranjana H.
    [J]. BLOOD, 2018, 131 (11) : 1183 - 1194
  • [8] Persistence of CD30 expression in Hodgkin lymphoma following brentuximab vedotin (SGN-35) treatment failure
    Nathwani, Nitya
    Krishnan, Amrita Y.
    Huang, Qin
    Kim, Young
    Karanes, Chatchada
    Smith, Eileen P.
    Forman, Stephen J.
    Sievers, Eric
    Thomas, Sandra H.
    Chen, Robert W.
    [J]. LEUKEMIA & LYMPHOMA, 2012, 53 (10) : 2051 - 2053
  • [9] Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma
    Pro, Barbara
    Advani, Ranjana
    Brice, Pauline
    Bartlett, Nancy L.
    Rosenblatt, Joseph D.
    Illidge, Tim
    Matous, Jeffrey
    Ramchandren, Radhakrishnan
    Fanale, Michelle
    Connors, Joseph M.
    Fenton, Keenan
    Huebner, Dirk
    Pinelli, Juan M.
    Kennedy, Dana A.
    Shustov, Andrei
    [J]. BLOOD, 2017, 130 (25) : 2709 - 2717
1